Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors
The field of genomics in myeloid malignancies and related implications in AML are evolving rapidly, and induction treatment strategies are now often guided by biological disease factors and fitness for intensive induction therapy. Familiarity with up-to-date risk stratification and targeted therapies is essential when formulating induction treatment strategies for newly diagnosed AML. 
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Case Studies in the Management of Leukemia
As a result of the therapeutic advances and clinical research affecting the management of patients with leukemia, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Evidence-Based Guidance on New Paradigms in the Treatment of Acute Myeloid Leukemia
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer
For some patients with localized prostate cancer, the treatment approach is determined by patient and disease characteristics. For others, advanced risk stratification with gene expression profiling or AI-derived digital histopathology biomarkers can help identify those who may derive greater or lesser absolute benefit from a given treatment, thus informing treatment decisions and reducing the chances of over- or under-treatment.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation